Odevixibat

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.

Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.

Journal: Alimentary pharmacology & therapeutics

Published: December 02, 2025

Remarkable Response to Odevixibat in an Adult With Progressive Familial Intrahepatic Cholestasis Type 1 and Intractable Pruritus.

Remarkable Response to Odevixibat in an Adult With Progressive Familial Intrahepatic Cholestasis Type 1 and Intractable Pruritus.

Journal: ACG case reports journal

Published: November 20, 2025

Odevixibat ameliorates high-fat diet-induced MASLD in mice by targeting the gut microbiota-metabolite axis and enhancing gut-liver crosstalk.

Odevixibat ameliorates high-fat diet-induced MASLD in mice by targeting the gut microbiota-metabolite axis and enhancing gut-liver crosstalk.

Journal: Journal of physiology and biochemistry

Published: November 18, 2025

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Ileal Bile Acid Transporter Inhibitors in Cholestasis: Potential for More Than Just Paediatrics?

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 17, 2025

Insights into Transport Function of the Murine Organic Anion-Transporting Polypeptide OATP1B2 by Comparison with Its Rat and Human Orthologues.

Insights into Transport Function of the Murine Organic Anion-Transporting Polypeptide OATP1B2 by Comparison with Its Rat and Human Orthologues.

Journal: Toxics

Published: November 06, 2025

Letter to The Editor, Regarding "Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis" Recently Published by Lacey and Colleagues.

Letter to The Editor, Regarding "Indirect Comparison of Maralixibat and Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis" Recently Published by Lacey and Colleagues.

Journal: Clinical therapeutics

Published: October 31, 2025

Odevixibat treatment for recurrent cholestasis in a patient with biallelic UNC45A variants causing osteo-oto-hepato-enteric syndrome.

Odevixibat treatment for recurrent cholestasis in a patient with biallelic UNC45A variants causing osteo-oto-hepato-enteric syndrome.

Journal: JHEP reports : innovation in hepatology

Published: October 17, 2025

An update on novel investigational agents for the treatment of primary biliary cholangitis.

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Journal: Expert opinion on investigational drugs

Published: October 13, 2025

Reply to: "Managing PFIC 7 with odevixibat: Alleviation of pruritus and biochemical response".

Reply to: "Managing PFIC 7 with odevixibat: Alleviation of pruritus and biochemical response".

Journal: JHEP reports : innovation in hepatology

Published: October 04, 2025

Acquired bisalbuminemia: A case report.

Acquired bisalbuminemia: A case report.

Journal: Clinical biochemistry

Published: September 18, 2025

Enantiomeric Resolution of Odevixibat via Immobilized Polysaccharide Columns: Impact of NP, RP, and PO Modes on LC-MS-Compatible Method Design.

Enantiomeric Resolution of Odevixibat via Immobilized Polysaccharide Columns: Impact of NP, RP, and PO Modes on LC-MS-Compatible Method Design.

Journal: Chirality

Published: August 29, 2025

Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis.

Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis.

Journal: European journal of pediatrics

Published: August 18, 2025

Showing 1-12 of 64

Last Updated: 04/28/2026